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Aplastic osteodystrophy without aluminum: The role of "suppressed"
parathyroid function. We evaluated 259 dialysis patients using serum
parathyroid hormone (P'I'H, IRMA; normal range Ito 5.5 PM or 10 to 55
pg/mi), the deferoxamine infusion test and iliac crest bone biopsy to
determine the various forms of renal osteodystrophy and their risk
factors, Although half of the biopsied patients had low turnover
osteodystrophy, evidence of aluminum toxicity was present in only 1/3
of them. Additional risk factors for this bone lesion included treatment
with peritoneal dialysis, ingestion of calcium carbonate, diabetes mel-
litus and advanced age. The PTH levels in patients with the aplastic
lesion were significantly lower than in patients with normal or high bone
turnover lesions [7.7 6.1 vs. 36.9 3.2 PM (77 61 vs, 369 32
pg/mi), P 'C 0.0001]. Aside from hypercalcemia, these patients were
relatively asymptomatic. In a second study, 10 patients on peritoneal
dialysis with the aplastic lesion had their dialysate calcium lowered
from 1,62 to 1.0 msi, This resulted in a significant increase in PTH
levels, from [3.7 0.8 to 10.6 1.9 M (37 8 to 106 19 pg/mI), P
<0.001] which persisted over the nine-month observation period. In
conclusion, the apiastic lesion is the most common form of renal
osteodystrophy, with aluminum intoxication implicated in only 1/3 of
the cases. In the remainder, factors identified include therapy with
pcritoneal dialysis using supraphysiological dialysate calcium, oral
CaCO3 intake and diabetes mellitus. These factors may modulate their
effect by lowering serum PTH to levels which are inadequate in
maintaining normal bone turnover. The long-term sequelae of this
non-aluminum related lesion remain to he defined.
Renal osteodystrophy is an important complication of pa-
tients on maintenance dialysis with significant associated mor-
bidity. Although osteitis fibrosa associated with secondary
hyperparathyroidism was a common finding in many dialysis
patients during the early years of maintenance dialysis, the
spectrum of bone disease has changed [1]. For example, during
the past decade, a form of low turnover osteodystrophy was
noted in patients presenting with non-healing fractures, bone
pain and proximal myopathy [2, 31. Histologically, osteomala-
cia or the aplastic lesion was found. Subsequent studies have
shown that aluminum was the major pathogenic factor in these
lesions [4]. In an attempt to reduce oral aluminum exposure,
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many dialysis patients had their phosphate binder therapy
switched from aluminum gels to calcium-based binders [5, 6].
Recently, we examined the spectrum of renal osteodystrophy
in a largely unselected group of hemo- and peritoneal dialysis
patients. To our surprise, the most common form of bone
disorder was the aplastic (adynamic, low turnover) lesion
which, in 2/3 of the cases, was not associated with significant
aluminum accumulation in bone. The clinical presentation of
this lesion and its possible pathogenesis are discussed.
Methods
The Renal Osteodystrophy Study was a prospective, cross
sectional study of renal bone disease in a largely unselected
population of dialysis patients in Toronto, Canada. Patients
were recruited from the Toronto General (42%), Wellesley
(34%) and Sunnybrook (24%) hospitals.
Study design and data collection
Since 1981, the Toronto Renal Failure Registry has prospec-
tively documented certain co-morbid events in all patients at
their entry into the End-Stage Renal Failure (dialysis and
transplantation) Program and annually thereafter in a comput-
erized data registry. We utilized the database from the Toronto
Renal Failure Registry on renal bone disease risk factors and
events for the initial assessment of bone disease in all the
dialysis patients at the study centers. All events entered into
our initial assessment database were confirmed from the pa-
tients' medical records and recorded in a standardized form by
the research assistant. Risk factors for bone disease assessed
included: patient age, sex, dialysis duration, dialysis modality,
diabetes mellitus, phosphate binder type, cumulative dose of
aluminum hydroxide gel ingested over the total time of dialysis,
previous parathyroidectomy and failed renal transplant. Clini-
cal parameters assessed included: musculoskeletal findings of
proximal myopathy (tested at the time of bone biopsy), unex-
plained bone pain or pathological fracture(s), and unexplained
neurological findings of ataxia, dyspraxia, seizure or dementia.
Laboratory parameters assessed included serum albumin, cal-
cium, phosphorus, alkaline phosphatase, aluminum, hemoglo-
bin and MCV. Hypercalcemia, defined as serum calcium
greater than 2.7 mivi (10.8 mg/dl), and unexplained microcytic
anemia, defined as hemoglobin less than 100 g/liter (10 g/dl) with
MCV < 80 fi excluding iron deficiency or thalassemia, were also
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noted. Serum calcium, phosphorus and alkaline phosphatase
were measured monthly for a total of six months prior to the
bone biopsy.
Each patient in the study was managed by his own nephrol.
ogist according to a standardized protocol. They were then
reassessed every three to four months for their clinical, labora-
tory and risk parameters for bone disease by the same research
assistant using a standardized form. All data were entered into
a computerized database specifically designed for the study.
Study patients
Four hundred and forty-five of all the "current" as well as
new patients entering either the hemo- or peritoneal dialysis
program in the study centers between October 1987 and July
1988 were assessed serially with a minimum follow-up of one
year during the study period. Of the 445 patients, 20 were
selected due to symptoms of bone disease while another 248
were randomly selected to undergo the special investigations
which included a bone biopsy, serum PTH measurement and a
deferoxamine infusion test (see below). Of the 268 patients
studied, the bone biopsy and/or deferoxamine test specimens
were lost in four; in five other patients the biopsy specimens
were inadequate for a pathologic diagnosis. Thus, the study
patients in this project consisted of 259 patients who have been
serially followed and had adequate data on all the special
investigations including bone biopsy. Once the patients com-
pleted the bone biopsy, this constituted an end point in the
study.
Of the patients who were not biopsied, 2/3 died or were
transplanted during the study and thus, were not available for
the special investigations. The clinical and risk parameters of
these patients for renal bone disease were not significantly
different from the patients who underwent a biopsy.
Special investigations
Serum was collected for intact 1-84 parathyroid hormone
(PTH) levels (drawn pre-heparinization in hemodialysis pa-
tients) and assayed by an immunoradiometric assay (IRMA) [7].
The normal range for healthy subjects without renal failure is 1
to 5.5 M (10 to 55 pg/ml). A deferoxamine (DFO) test was
performed using a dose of 40 mg/kg which was administered i.v.
in patients on hemodialysis and i.p. in patients on CAPD and
IPD. In hemodialysis and IPD patients, post-DFO serum alu-
minum levels were determined after 48 and 72 hours, respec-
tively, just prior to initiation of the next dialysis treatment [8].
In CAPD patients, these levels were determined 24 hours after
i.p. instillation of deferoxamine [9]. All aluminum-containing
medications, including aluminum hydroxide and carbonate, as
well as sucralfate, were discontinued 48 hours prior to baseline
plasma aluminum collection and restarted after the second,
post-deferoxamine plasma aluminum sampling. Plasma alumi-
num was collected in special trace mineral tubes and measured
by Dr. S. Krishnan (Medical Physics Laboratory, Toronto
General Hospital) using graphite furnace atomic absorption
spectrophotometry with a normal reference range <560 nvi (100
nM = 2.7 pjg/liter). Bone from a subset of the aplastic patients
(19%) was assayed for total aluminum content by atomic
absorption spectrophotometry by Dr. A. Alfrey (Denver, Col-
orado, USA) [10]. Serum osteocalcin levels (bone GLA protein,
BGP) were assayed by radioimmunoassay by Nichols Institute
using rabbit antibody to bovine and radiolabeled BGP [11] in
88% of patients.
Bone biopsy
Under local anesthesia, bone biopsy specimens were taken
from the anterior iliac crest using a Bordier needle. Patients
were given two courses of different tetracyclines separated by a
17-day drug-free period to label their bones for calculation of
bone formation rates. The biopsy was performed four to 10 days
after the last dose of tetracycline. Bone biopsies were assessed
for static and dynamic histomorphometric parameters.
Histomorphometric analysis of Goidner stained sections was
performed as previously described [12]. Separate sections were
also stained with aurin-tricarboxylic acid for the identification
of aluminum on a mineralizing bone surfaces [13] and Prussian
blue for the detection of iron.
Dynamic measurements performed on unstained trabecular
sections included bone apposition rate (pm/day) and the length
of double-labeled surfaces (as percent of total bone surface and
as percent of osteoid surface). From these v dues the bone
formation rate (BFR) at the tissue level was de ived by multi-
plying the bone apposition rate (uncorrected) by the double-
labeled surfaces [14].
Classification of biopsies
Biopsies were classified as previously described [12, 14]: mild
osteodystrophy (osteoid area (OA) < 15%; fibrosis area <
0.5%; BFR  108 jsm2/mm2 tissue area/day); osteitis fibrosa
(OA < 15%; fibrosis area  0.5%); osteomalacia (OA  15%;
fibrosis area < 0.5%); mixed (OA  15%; fibrosis area 0.5%);
aplastic lesion (OA < 15%; fibrosis area < 0.5%; BFR < 108
sm2/mm2 tissue area/day). Low-turnover renal osteodystrophy
was defined by a BFR < 108 which is below the lowest limit of
our normal range, 108 to 500 sm2/mm2 tissue area/day. This
comprised the aplastic and osteomalacia groups. Aluminum-
associated bone disease was defined as those bone biopsies that
demonstrated aluminum staining on  25% of their mineralized
bone surface, and in which the bone formation rate was below
normal [15, 16]. Normal or elevated BFR was found in associ-
ation with numerous active osteoblasts and multinucleated
osteoclasts and included the mild, osteitis fibrosa and mixed
lesions; these lesions formed the normal and high turnover
osteodystrophy group.
Second study
In a separate study, the dialysate calcium of 10 CAPD
patients with the aplastic lesion, five demonstrating < 25% and
five with  25% surface aluminum staining, was lowered from
the customary concentration of 1.62 to 1.0 m. These patients
were selected on the basis of having developed serum ionized
hypercalcemia (ionized calcium > 1.35 mM) while ingesting
calcium carbonate. Monthly serum ionized calcium, phospho-
rus and PTH were measured thereafter for nine months. The
patients' serum phosphorus was controlled by the combination
of aluminum gels and calcium carbonate. None of the patients
was ingesting vitamin D.
Statistical analysis
All descriptive data are expressed as means SEM, or
percent. One-way analysis of variance was used for continuous

 



variables and the chi-square test (or Fisher's exact test if
appropriate) for binary variables. For multiple group compari-
sons, Tukey's procedure was performed. Statistical analysis
was performed using the SAS software program [17].
Results
General patient characteristics
The mean age of our 259 study patients was 57 1 years, and
the mean dialysis duration at the time of the bone biopsy was
41 0.2 years. The male to female ratio was 3:2. Forty-five
percent were treated with hemodialysis, 45% with CAPD, and
10% were on twice weekly IPD.
Of the 259 study patients 128 (49.4%) had the aplastic lesion,
making this the most common finding in our study (Fig. 1).
Osteomalacia, the other form of low turnover osteodystrophy,
accounted for only 4.2% of the total. The remaining patients
had normal or high turnover lesions, that is, mild (17.7%),
fibrosis (22.5%) and mixed (6.2%).
Aplastic osteodystrophy: Aluminum as a possible factor
As aluminum intoxication is commonly associated with low
turnover osteodystrophy [18, 19] we looked, by varied meth-
ods, at this possible etiologic factor for the aplastic lesion.
One-third of patients with the aplastic lesion had stainable bo.ie
surface aluminum of  25% which is a cut-off commonly used
for diagnosis of symptomatic aluminum-related bone disease
[20] (Fig. 2, Table 1). Patients within this group had a signifi-
cantly longer period of aluminum gel therapy, and consequently
total cumulative aluminum exposure (Table 2). They had higher
deferoxamine test results than the aplastic patient with <25%
stainable bone surface aluminum or the patients with the mild
lesion. As well, they had a higher bone aluminum content.
Patients with 5% aluminum staining on bone biopsy had the
least cumulative dose of aluminum gels and 2/3 of them had no
previous history of therapy with oral aluminum gels or sucral-
fate (Table 2).
Clinically, patients with  25% surface aluminum had a
markedly increased frequency of complications of bone dis-
ease, including bone pain, proximal myopathy, and pathologic
fracture(s) (Table I, Fig. 3). They also had a greater incidence
of microcytic anemia and episodic hypercalcemia. Patients wil h
 25% aluminum were more likely to have had previol s
parathyroidectomy or a failed transplant. The risk factors for
the aplastic patients with < 25% aluminum, as compared to
those with  25%, differed markedly, as seen below. Also,
patients with the mild lesion, with normal bone formation rates,
actually had higher surface stainable aluminum levels than the
aplastic patients with intermediate or low levels of aluminum
staining, 19.2 3.0 versus 12.7 0.8 versus 1.8 0.3%,
respectively. Consequently, in the majority of patients with the
aplastic lesion, aluminum could not be clearly implicated as an
etiologic factor, even though the lesions appeared similar his-
tologically.
Aplastic osteodystrophy: Non-aluminum factors
To better ascertain potential etiologies of the aplastic lesion
demonstrating less than 25% aluminum staining of bone sur-
faces, we compared this subgroup to the patients with high
turnover bone disorders, that is, the fibrotic and mixed lesions,
the patients with the mild lesion, who exhibited normal
bone formation rates (Table 1). When compared to patients with
high-turnover bone disorders, those with the aplastic lesion had
a higher preponderance of patients on peritontal dialysis, with
diabetes, and a shorter dialysis duration. This aplastic group
also tended to be older. Furthermore, this group was the least
likely to be treated with vitamin D and the most likely to be
treated with calcium carbonate as the sole phosphate-binding
agent. Although no significant differences were noted in serum
calcium or phosphorus levels the aplastic group had the lowest
PTH levels. Markers of bone turnover, such as, alkaline phos-
phatase and BGP, were significantly lower in the aplastic group.
Hypercalcemia was the oly significant abnormality noted in
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Osteomalacia
Fig. 1. A. The different lesions noted among the 259
biopsied patients. B. The prevalence of surface
aluminum staining in the patients with aplastic
lesions. The group is arbitrarily divided into those
with  5% (38.3%), 6 to 24% (30.5%) and 25%
(31.2%) of their bone surface stained for aluminum.
0)
C
a)
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Bone surtace aluminum staining, %
Fig. 2. The number of aplastic patients (y axis) with increasing degrees
of surface aluminum staining, as denoted by 5% increments (x axis).
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Table 1. Clinical and biochemical comparison of patients with aplastic, mild and high turnover (OF/mixed) bone lesions
Aplastic (surface aluminum)
Mild OF/mixed P5% 6 to 24% > 25%
Clinical findings
N 49 39 40 33 69
Age at biopsy
Peritoneal dialysis %
CaCO3 alonec %
Vitamin D %
59 2.2
82
67
0
61 2.0
72
26
0
57 2.1
45
0
2
54 2.7
80
12
19
53 2.7
26
28
16
< o.o2
< 0.000l
<00001b
< 0.04a
ESRD duration years
Diabetes %
1.7 0.2
44
2.2 0.2
24
5.3 10.8
31
3.3 0.6
40
4.8 0.6
7
<0.000la
<0.OOla
Failed transplant %
PTX %
6
0
10
0
22
10
10
7
20
2
<0.027"
<0.015"
Findings of bone disease
Bone pain %
Proximal myopathy %
Pathologic fractures %
Neurologic findings %
Microcytic anemia %
Hypercalcemia %
2
8
2
0
0
10
3
10
0
0
5
33
42
69
12
8
22
65
6
9
0
0
3
15
38
48
9
0
3
36
< 0.0001''
< 0.0001"
<
<0045b
<00001b
< 0.000lb
Biochemical results
PTHpM 6.6 0.8 8.9 1.1 7.9 0.9 15.8 2.3 50,2 6.0 <0.000la
Ca mw 2.3 0.03 2.4 0.03 2.5 0.04 2.4 0.4 2.4 0.6 NS
P04 mM 1.7 0.06 1.9 0.08 1.9 0.1 1.8 0.06 2.0 0.01 NS
ALP lU/liter 72 5 75 6 74 5 84 10 170 19 < O.OOIa
BGP /hg/lirer 80 10 73 14 74 14 262 107 866 204 <0.000la
a Difference among the bone groups, excluding aplastic with  25% surface aluminuim
ID Difference among 3 subgroups of aplastic lesion.
Treated with CaCO3 alone with no previous exposure to aluminum gels; OF/mixed, osteitis fibrosa and mixed lesions; ESRD, end-stage renal
disease; PTX, parathyroidectomy; Tx, kidney transplant; ALP, alkaline phosphatase: normal, 38 to 110 U/liter; PTH: normal, ito 5.5 M or 10—55
pg/mi; BGP, bone GLA protein, normal 16 to 92 pg/liter; Ca, calcium; P04, phosphate.
Table 2. Aluminum as a factor in the aplastic lesion
Aluminum as a factor
Aplastic (surface aluminum)
Mild P5% 6—24%  25%
Al gel therapy months 6.8 2.2 10.5 1.9 46.4 16.5 17.7 4.6 <0.0001
Cumulative Al dose kg 1.0 0.2 2.2 0.3 3.4 0.2 1.5 0.4 < 0.0001
CaCO3 alonea % 67 26 0 12 <0.0001
Plasma Al nM 869 153 853 111 2500 302 706 105 <0.0001
PlasmaAlnM 919±1127 1188± 181 4782 1407± 146 <0.0001
Bone Al mg/kg dry wt 12.8 4.3
(12)''
24.0 8.1
(7)
46.8 12.3
(5)
— <0.0014
Bone surface aluminum % 1.8 0.3 12.7 0.8 44.1 2.4 19.2 3.0 <0.001
Abbreviations are: Al, aluminum; SAl, rise in plasma aluminum after deferoxamine. P value signifies difference among 4 groups.
a Treated with CaCO3 alone, with no previous exposure to aluminum gels
b Number of patients tested in each group
the <25% group, occurring in 25% of patients at least once
during the study period.
On comparing the aplastic with the mild group demonstrating
normal bone formation rates, numerous similarities were noted.
The only clear cut differences were that the mild group was less
likely to have received therapy with calcium carbonate alone,
had been on dialysis slightly longer, and had higher PTH levels.
None of the aplastic biopsies, and in particular those with
<25% surface aluminum, had any evidence of iron staining.
Effects of dialysate concentration on PTH levels
In the second study, the serum phosphorus of the 10 study
patients with the aplastic lesion was controlled with calcium
carbonate, 1350 241 mglday. Five of the patients required
supplemental aluminum gels due to development of serum
ionized hypercalcemia with higher doses of calcium salts.
Switching the patients from their customary supraphysiological
dialysate calcium concentration of 1,62 to 1.0 m allowed for
the aluminum gels to be discontinued in all patients. Thus,
serum phosphorus could be controlled with calcium carbonate
alone, 1625 187 mg/day. Serum ionized calcium normalized
and PTH rose, from the baseline level of 3.7 0.8 to 10.6 1.9
pM, P < 0.001, after the first month. After nine months of
follow-up, serum ionized calcium remained in the normal range,
1.15 to 1.35 m, while serum PTH remained at the same levels
(Fig. 4).
Discussion
We have found that 50% of a largely unselected group of
dialysis patients had low-turnover aplastic osteodystrophy, a


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lesion previously associated mainly with aluminum intoxica-
tion. However, only 1/3 of these patients had evidence of
significant aluminum accumulation. Symptoms of bone pain,
fractures and proximal myopathy occurred nearly exclusively
in the subgroup of patients with excess aluminum accumula-
tion. The remaining 2/3 of patients were largely asymptomatic,
aside from the occasional episode of hypercalcemia while
ingesting calcium carbonate. Since the subgroup with < 25%
surface aluminum had been on dialysis for an average of two
years only, it is conceivable that symptoms may develop in the
future as the dialysis duration of this group lengthens.
Whether a low turnover state in the absence of aluminum is
necessarily deleterious on a long-term basis has yet to be
determined. Other studies have demonstrated, however, that
conditions associated with low bone turnover states predispose
to aluminum accumulation and morbidity [23]. Consequently,
the presence of diabetes mellitus, previous parathyroidectomy
or transplant, may predispose to an earlier development of
aluminum-related bone disease, as compared to uremic patients
ingesting the same dose of aluminum gels without these risk
factors [24—26]. Conceivably, the group demonstrating interme-
diate aluminum staining (surface aluminum 6 to 24%) might be
in transition and may progress with time and further aluminum
exposure to clinically apparent aluminum-related bone disease.
The aplastic lesion associated with aluminum intoxication
was indistinguishable histologically from that without signifi-
cant aluminum staining (Table 3). However, by all known
criteria for assessing aluminum loading (such as cumulative
aluminum dose ingested since dialysis was initiated, deferox-
amine test results, bone alUminum content) there were signifi-
cant differences between the aplastic group with < 25 versus 
25% aluminum staining. Although other aluminum stains may
be more sensitive [271, they lack clinico-pathologic correla-
tions. In addition, aluminum staining of  25% of bone surfaces
as detected by the aurin-tricarboxylic acid stain, appears to be
a useful arbitrary "cutoff" that distinguishes those with symp-
tomatic bone disease [20].
Other groups have also noted the emergence of the aplastic
lesion as patients are switched from aluminum gels to calcium
salts for serum phosphate control [28, 291, Some have hypoth-
esized that vitamin D might be pathogenic [29]. Only 12% of our
0 1—3 4—6 7—9
Time, months
Fig. 4. Decreasing dialysate calcium from 1.62 to 1.0 mM in 10 CAPD
patients with the aplastic lesion resulted in normalization of serum
ionized calcium levels (U), P < 0.0001, and increased serum PTH
concentrations (•), P < 0.003, by analysis of variance. Each period
covers 3 months of therapy. Normal serum levels of ionized Ca: 1.15 to
1.30 mM; PTH: Ito 5.5 pM.
patients were receiving vitamin D so that other factors must be
implicated. Also, the percentage of patients on vitamin D
supplements was similar in the hemodialysis and peritoneal
dialysis (11 and 14%, respectively) treatment groups, yet there
was a clear predilection of this lesion for patients treated with
peritoneal dialysis.
The possible contribution of iron overload as a cause of low
bone turnover had been ruled out with the negative stain for
bone iron [30]. Also, no significant difference in serum phos-
phorus was noted among the different bone groups or in patients
treated with hemodialysis versus peritoneal dialysis, ruling out
this possible cause of depressed bone turnover [31]. Further-
more, neither parathyroidectomy nor previous transplantation,
risk factors associated with low bone turnover states, was noted
to be increased in the non .aluminum-related aplastic group.
The finding that the aplastic group had the lowest PTH levels
among all the bone subgroups may indicate an important
pathogenic factor, Continuous exposure to supraphysiological
dialysate calcium (1.62 mM) in CAPD patients, in association
with oral calcium carbonate, may result in greater net positive
calcium transfer [321. That, in turn, may result in a greater
frequency of hypercalcemia and relative suppression of para-
thyroid hormone secretion, as compared to hemodialysis pa-
tients who aEe only intermittently exposed to elevated calcium
levels. This is consistent with our previous finding that the
incidence of serum ionized hypercalcemia was higher in CAPD
as compared to hemodialysis patients (2.1 0.3 vs. 0.5 0.1
episodes/patient-year, P < 0.001) [33]. Coincidentally, mean
serum PTH levels in peritoneal dialysis patients were signifi-
cantly lower than levels observed in hemodialysis patients (13.3
1.2 vs. 30.3 3.4 p, P < 0.001). Consequently, these lower
PTH levels may explain the 77% prevalence of the aplastic
lesion observed in patients on peritoneal dialysis. These effects
are modulated without the benefit of vitamin D.
Both insulin and non-insulin dependent diabetes mellitus are
associated with depressed PTH levels and bone formation rates
[34]. In this study, diabetes was also a risk factor for low
80
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Bone surface aluminum stain, %
Fig. 3. The prevalence of bone pain, pathologic fracture(s) and hyper-
calcemia in patients with aplastic lesions, as differentiated by the
degree of bone surface aluminum staining. Symbols are: (El) bone pain;
() pathologic fracture(s); (•) hypercalcemia.
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Table 3. Bone histomorphometric data
turnover osteodystrophy. This was confirmed as an indepen-
dent risk factor despite the preponderance of diabetics on
peritoneal dialysis. Recently, Sugimoto et al demonstrated in an
in vitro model that glucose and insulin independently modulate
parathyroid hormone release [35]. Thus, the low turnover
osteodystrophy in these patients may also be modulated via
relatively suppressed PTH levels.
Lowering of dialysate calcium in the 10 aplastic patients that
were studied resulted in a threefold increase of their PTH
levels. This demonstrates that the parathyroid-calcium axis is
not irreversibly suppressed by aluminum or chronic hypercal-
cemia, and raises the possibility that bone turnover can be
increased by raising circulating PTH levels. If a higher bone
turnover is beneficial, it is possible that this may be induced in
time with such PTH stimulation.
The association of the aplastic lesion with PTH levels less
than two times the upper limit of normal suggests a useful test
for detecting this lesion, especially when evaluating patients
with hypercalcemia. Low baseline and deferoxamine stimulated
serum aluminum levels help to further differentiate the aplastic
subgroups, that is, those with  25% versus < 25% surface
aluminum. This differentiation is also simplified if the patient in
question has symptomatic bone disease.
The finding of a normal bone formation rate, in the mild
group, in association with a mean PTH level that was three
times the upper limit of normal defined for non-uremic subjects,
suggests that such higher PTH levels are required in uremia to
normalize bone turnover. Most likely this effect can be ascribed
to resistance of uremic bone to the actions of PTH [21, 22]. The
fact that the "mild" patients had normal bone turnover in the
face of higher bone surface aluminum levels than the non-
aluminum related aplastic patients further confirms that alumi-
num is not pathogenic in the latter but rather the relatively
depressed PTH levels.
The spectrum of renal osteodystrophy is a dynamic phenom-
enon, changing from year to year in individual patients and in
cross section as therapy is modified. Increased use of peritoneal
dialysis with supraphysiological dialysate calcium, calcium-
based phosphate binders and the increasing percentage of
diabetics and older patients comprising the dialysis population
will influence the prevalence of bone diseases obsi rved. With
the current treatment regimen, low turnover lesion; now com-
prise the largest group. While aluminum is implica Led in 1/3 of
these patients, in the remainder, a relatively suppressed PTH
level seems to be the main pathogenic factor. Clearly, all
potential sources of aluminum should be curtailed in the aplas-
tic patients for fear of precipitating aluminum bone disease.
Vitamin D, per Se, has no beneficial role to play in this lesion.
In fact, its use may further suppress PTH release, resulting in
further depression of bone turnover. Clearly, long-term studies
are indicated to define the natural history and ideal modality of
treatment of this lesion.
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Aplastic
Mild Normala p
 5% 6 to 24%  25%
Total bone area 20.1 0.9 18.5 09 20.5 0.9 21.5 0.8 21.3 0.6 NS
% tissue area
Osteoid area 4.3 0.5 5.0 0.5 5.4 0.5 5.8 0.5 3.5 0.2 NS
% total bone area
Fibrosis area 0.04 0.03 0.01 0.004 0.03 0.01 0.2 0.2 0 NS
% tissue area
Osteoid surface 39.5 3.3 43.0 2.8 44.9 3.2 45.0 2.5 20.3 0.2 NS
% bone surface
Eroded surface 6.5 0.4 5.8 0.5 6.8 0.6 10.3 0.7 5.5 0.3 <0.001
% bone surface
Mineral apposition rate 0.4 0.05 0.5 0.06 0.5 0.06 0.8 0.03 0.65 0.02 <0.001
piday
Surface aluminum % 1.8 0.3 12.7 0.8 44.1 2.4 19.2 3.0 0 <0.001
Osteoblast surface 0.36 0.06 0.48 0.10 0.62 0.17 1.63 0.16 2.20 0.2" <0.001
% of bone surface
Osteoclasts 0.22 0.04 0.22 0.04 0.26 0.04 0.68 0.06 0.65 0.05c <0.001
# cells/mm bone surface
Bone formation rate 21 4 28 5 26 5 247 21 307 17 <0.001
i.un2/mm2 of tissue area/day
P value signifies difference among 3 aplastic groups and mild.
a 79 normal subjects had static measurements; 42 had dynamic measurements (mineral apposition rate and
b Osteoblast surface normals based on data from 84 biopsies.
c Osteoclast cell number normals based on 19 biopsies.
bone formation rate).


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